Summary:

- The article reports on the development of a new class of small-molecule inhibitors targeting the SARS-CoV-2 main protease (Mpro), which is essential for viral replication.
- The inhibitors, dubbed "SLAMmers," were designed to bind to the Mpro active site and disrupt its function, effectively blocking the virus's ability to replicate.
- Experiments in cell culture and animal models demonstrated the potent antiviral activity of the SLAMmer compounds, suggesting they could be promising candidates for the development of COVID-19 therapeutics.